RBC Capital Comments on Biogen (BIIB) and Tecfidera PML Case; Analyst Maintains Outperform Rating

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. AMZN
10. META

Go back to RBC Capital Comments on Biogen (BIIB) and Tecfidera PML Case; Analyst Maintains Outperform Rating

Baird Upgrades Biogen (BIIB) to Outperform

October 22, 2014 12:45 PM EDT

Baird upgraded Biogen (NASDAQ: BIIB) from Neutral to Outperform with a price target of $382.00.

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $326.77 yesterday.

... More

Biogen Idec (BIIB) Says Tecfidera Patient Who Died had Low White Blood Cell Counts

October 22, 2014 11:52 AM EDT

Biogen Idec Inc. (BIIB) is seeing some unnecessary weakness Wednesday following Q3 results and the company's conference call.

Earlier, the WSJ cited the company as saying it confirmed a... More

Biogen (BIIB): Deutsche Bank Comments on Recent Weakness And Compares it to Celgene (CELG)

October 22, 2014 10:52 AM EDT

Deutsche Bank maintained a Buy rating on Biogen (NASDAQ: BIIB) with a price target of $430. Analyst Robyn Karnauskas commented on recent weakness and compared the stock to Celgene (NASDAQ: CELG). Overall, she is positive on both stocks.

"Biogen is trading weak post earnings due to 1) slower sequential revenue growth and 2) One PML case with Tecfidera disclosed on todays call. While we note that there is a good risk/reward... More

Biogen Idec (BIIB) Tops Q3 EPS by 31c; Boosts FY14 EPS Outlook

October 22, 2014 7:06 AM EDT

Biogen Idec (NASDAQ: BIIB) reported Q3 EPS of $3.80, $0.31 better than the analyst estimate of $3.49. Revenue for the quarter came in at $2.5 billion versus the consensus estimate of $2.48 billion.

The third quarter was a period of significant achievement as we continued to make progress against our... More